CR8630A - Solidos supersaturados estabilizados de drogas lipofilicas - Google Patents

Solidos supersaturados estabilizados de drogas lipofilicas

Info

Publication number
CR8630A
CR8630A CR8630A CR8630A CR8630A CR 8630 A CR8630 A CR 8630A CR 8630 A CR8630 A CR 8630A CR 8630 A CR8630 A CR 8630A CR 8630 A CR8630 A CR 8630A
Authority
CR
Costa Rica
Prior art keywords
lipofilic
supersatured
drugs
solids
stabilized
Prior art date
Application number
CR8630A
Other languages
English (en)
Inventor
Adrian Funke
Torsten Wagner
Ralph Lipp
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR8630(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR8630A publication Critical patent/CR8630A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invencion se refiere a una composicion farmaceutica con disolucion de drogas lopofilicas mejoradas en un medio acuoso. Se comprobo que composiciones farmaceuticas que comprenden un polvo de compuestos lipofilicos tales como hormonas, y esteroides (por ejemplo, drospirenona y valerato de estradiol) en forma dispersa a nivel molecular junto a un vehiculo que posee un area superficial especifica de al menos 250 m2/g, tal como dioxido de silicio, por ejemplo, dioxido de silicio comercializado bajo la denominacion Aeroperl «, posee mejores propiedades de disolucion de la droga lipofilica.
CR8630A 2004-03-10 2006-09-14 Solidos supersaturados estabilizados de drogas lipofilicas CR8630A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55133004P 2004-03-10 2004-03-10
EP04075714 2004-03-10

Publications (1)

Publication Number Publication Date
CR8630A true CR8630A (es) 2007-06-06

Family

ID=34928105

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8630A CR8630A (es) 2004-03-10 2006-09-14 Solidos supersaturados estabilizados de drogas lipofilicas

Country Status (32)

Country Link
US (1) US8715735B2 (es)
EP (2) EP1765290B1 (es)
JP (1) JP5006185B2 (es)
KR (1) KR101210695B1 (es)
CN (1) CN1984644B (es)
AR (1) AR048500A1 (es)
AT (1) ATE442131T1 (es)
AU (1) AU2005221403B8 (es)
BR (1) BRPI0507342A (es)
CA (1) CA2558582C (es)
CR (1) CR8630A (es)
DE (1) DE602005016551D1 (es)
DK (1) DK1765290T3 (es)
EA (1) EA012746B1 (es)
EC (1) ECSP066902A (es)
ES (2) ES2390406T3 (es)
GT (1) GT200500045A (es)
HR (1) HRP20090614T1 (es)
IL (1) IL177894A0 (es)
MY (1) MY142989A (es)
NO (1) NO20064473L (es)
NZ (1) NZ549793A (es)
PA (1) PA8626101A1 (es)
PE (1) PE20060016A1 (es)
PL (1) PL1765290T3 (es)
PT (1) PT1765290E (es)
RS (1) RS51076B (es)
SI (1) SI1765290T1 (es)
SV (1) SV2005002044A (es)
TW (1) TWI345986B (es)
UY (1) UY28803A1 (es)
WO (1) WO2005087199A2 (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172810B2 (en) 2003-02-24 2019-01-08 Pharmaceutical Productions, Inc. Transmucosal ketamine delivery composition
CN101232869B (zh) * 2005-06-16 2016-03-02 沃纳奇尔科特有限责任公司 局部给药的凝胶组合物
CA2612380C (en) * 2005-06-16 2017-06-06 Warner Chilcott Company, Inc. Estrogen compositions for vaginal administration
US20090312439A1 (en) * 2006-05-10 2009-12-17 Ralph Hofmann Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
JP5600058B2 (ja) * 2007-04-11 2014-10-01 ファーマシューティカル プロダクションズ， インコーポレイテッド メラトニンタブレットならびに調剤及び使用方法
BRPI0908477A2 (pt) * 2008-02-13 2018-03-27 Bayer Schering Pharma Ag sistema de distribuição de medicamento contendo estradiol
CN102083467B (zh) * 2008-03-11 2013-12-25 Aska制药株式会社 固体分散体及其药物组合物、以及它们的制备方法
SI2296633T1 (sl) 2008-05-02 2015-11-30 Gilead Sciences, Inc. Uporaba trdnih nosilnih delcev za izboljšanje predelovalnih sposobnosti farmacevtskega sredstva
WO2009138224A1 (en) * 2008-05-14 2009-11-19 Helm Ag Pharmaceutical composition comprising drospirenone
EA022208B1 (ru) * 2008-10-10 2015-11-30 Тева Вимен'С Хелс, Инк. Способы лечения вазомоторных симптомов у кастрированных пациентов с раком предстательной железы низкими дозами ципротерона ацетата
US20120064166A1 (en) * 2009-02-18 2012-03-15 Bayer Pharma Aktienesellschaft Formulation comprising drospirenone for subcutaneous or intramuscular administration
CN102413813B (zh) * 2009-03-24 2014-11-12 Adds制药有限责任公司 用于口服递送的稳定化的溶解性增强的制剂
FR2947178B1 (fr) * 2009-06-29 2012-07-06 Effik Composition pharmaceutique a base de progesterone micronisee et ses utilisations
AR081670A1 (es) 2010-06-29 2012-10-10 Leon Farma Sa Lab Composicion farmaceutica que comprende drospirenona y kit anticonceptivo
US10849857B2 (en) 2010-07-28 2020-12-01 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
US11351122B1 (en) 2010-07-28 2022-06-07 Laboratorios Leon Farma Sa Synthetic progestogens and pharmaceutical compositions comprising the same
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
WO2012120365A1 (en) 2011-03-07 2012-09-13 Aurobindo Pharma Limited Stable pharmaceutical composition comprising ethinyl estradiol
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE051406T2 (hu) 2012-11-14 2021-03-01 Grace W R & Co Biológiailag aktív anyagot és rendezetlen szervetlen oxidot tartalmazó kompozíciók
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20140303128A1 (en) * 2013-03-14 2014-10-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
AU2015292915B2 (en) 2014-07-21 2020-10-15 Pharmaceutical Productions, Inc. Solid dosage form composition for buccal or sublingual administration of cannabinoids
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN106109420B (zh) * 2016-08-11 2018-07-06 吴启旸 依普利酮固体分散体及其制剂
ES2899218T3 (es) * 2017-02-14 2022-03-10 Dsm Ip Assets Bv Formulaciones dispersables en agua
EP3582627B1 (en) * 2017-02-14 2021-09-01 DSM IP Assets B.V. Storage-stable formulations
CN110013467B (zh) * 2018-01-10 2021-09-17 上海汉都医药科技有限公司 一种固体微粒及其制备方法和含其的药物组合物
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
JP2022069437A (ja) * 2020-10-23 2022-05-11 富士製薬工業株式会社 医薬製剤およびその製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA72698B (en) * 1972-02-03 1973-09-26 Liebenberg R W Method of preparing medicinal compositions
US4013785A (en) * 1975-03-21 1977-03-22 Bristol-Myers Company Apap tablet containing fumed silica and process for manufacturing same
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
GB8403359D0 (en) 1984-02-08 1984-03-14 Erba Farmitalia Pharmaceutical compositions
IT1216570B (it) * 1988-04-08 1990-03-08 Vectorpharma Int Composizione farmaceutiche a rilascio controllato e procedimento per la loro preparazione.
DE3916112A1 (de) * 1989-05-16 1990-11-22 Schering Ag Dihydrospirorenon als antiandrogen
CA2050067C (en) 1990-08-30 2000-05-30 Yasushi Morita Controlled drug release composition
ATE118178T1 (de) * 1990-11-29 1995-02-15 Faulding F H & Co Ltd Verfahren zur herstellung von flüssigkeiten enthaltenden pulvern.
DE4326240A1 (de) * 1993-08-02 1995-02-09 Schering Ag 15,15-Dialkyl-substituierte Derivate des Estradiols
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
US5800834A (en) 1996-06-10 1998-09-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
KR20000000016A (ko) 1999-02-10 2000-01-15 김일 자동차용번호판부착볼트구조
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
SI1598069T1 (sl) * 1999-08-31 2009-10-31 Bayer Schering Pharma Ag Farmacevtska kombinacija etinilestradiola in drospirenona za uporabo kot kontracepitev
PT1611892E (pt) 2000-01-18 2009-11-20 Bayer Schering Pharma Ag Composições farmacêuticas compreendendo drospirenona
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
CZ20033456A3 (en) * 2001-06-22 2004-07-14 Pfizer Products Inc. Pharmaceutical compositions comprising adsorbates of amorphous drug
ITMC20010031U1 (it) 2001-07-05 2003-01-07 Best Raffaello Srl Recipiente di cartone ad uso alimentare, dotato di un tratto anulare superiore asportabile a strappo
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
WO2004022065A1 (en) 2002-09-05 2004-03-18 Pantarhei Bioscience B.V. Pharmaceutical application of 15- or 16- substituted testosterone analogues
DE60330888D1 (de) 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
DE20217332U1 (de) 2002-11-11 2003-02-27 Brand Factory Swiss Gmbh, Rotkreuz Socke
CA2516096A1 (en) * 2003-02-19 2004-09-02 Lifecycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
KR20060130723A (ko) 2004-03-10 2006-12-19 쉐링 악티엔게젤샤프트 분자 분산된 드로스피레논을 포함하는 조성물

Also Published As

Publication number Publication date
SI1765290T1 (sl) 2010-01-29
ES2332229T3 (es) 2010-01-29
US20050207990A1 (en) 2005-09-22
JP5006185B2 (ja) 2012-08-22
TWI345986B (en) 2011-08-01
GT200500045A (es) 2005-10-31
PL1765290T3 (pl) 2010-02-26
CN1984644B (zh) 2010-12-08
WO2005087199A2 (en) 2005-09-22
EP1765290B1 (en) 2009-09-09
PA8626101A1 (es) 2006-07-03
KR101210695B1 (ko) 2012-12-11
CA2558582A1 (en) 2005-09-22
US8715735B2 (en) 2014-05-06
BRPI0507342A (pt) 2007-07-03
AU2005221403B8 (en) 2010-01-07
ES2390406T3 (es) 2012-11-12
RS51076B (sr) 2010-10-31
HK1103660A1 (en) 2007-12-28
EP1765290A2 (en) 2007-03-28
UY28803A1 (es) 2005-10-31
EP2087883B1 (en) 2012-07-25
TW200600116A (en) 2006-01-01
HRP20090614T1 (hr) 2009-12-31
PE20060016A1 (es) 2006-02-16
NO20064473L (no) 2006-10-10
ATE442131T1 (de) 2009-09-15
MY142989A (en) 2011-02-14
DE602005016551D1 (de) 2009-10-22
CA2558582C (en) 2013-07-16
EA200601588A1 (ru) 2007-02-27
WO2005087199A3 (en) 2009-01-15
AU2005221403A1 (en) 2005-09-22
AR048500A1 (es) 2006-05-03
EP2087883A1 (en) 2009-08-12
CN1984644A (zh) 2007-06-20
KR20060132999A (ko) 2006-12-22
ECSP066902A (es) 2006-12-20
NZ549793A (en) 2010-06-25
EA012746B1 (ru) 2009-12-30
SV2005002044A (es) 2005-11-04
DK1765290T3 (da) 2009-11-02
JP2007528389A (ja) 2007-10-11
AU2005221403B2 (en) 2009-12-10
WO2005087199A8 (en) 2007-03-29
PT1765290E (pt) 2009-11-23
IL177894A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
CR8630A (es) Solidos supersaturados estabilizados de drogas lipofilicas
IL177893A0 (en) Compositions comprising drospirenone molecularly dispersed
Lu et al. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs
MX336930B (es) Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
EA200900572A1 (ru) Мицеллярные наночастицы с химическими субстанциями
WO2012075081A3 (en) High-strength testosterone undecanoate compositions
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2008061014A3 (en) Self-assembling peptide amphiphiles for tissue engineering
BRPI0607549A2 (pt) sistemas de distribuição farmacêutica para fármacos hidrófobos e composições compreendendo os mesmos
MXPA05002814A (es) Formulacion para agentes lipofilicos.
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
WO2008070538A3 (en) Micellar nanoparticles comprising botulinum toxin
UA107582C2 (uk) Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю
EP2476461A3 (en) Formulations For Cancer Treatment
WO2007150075A3 (en) Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
PA8853801A1 (es) Composición de liberación pulsátil de sildenafil y proceso para prepararla
CU20060177A7 (es) Soluciones sólidas supersaturadas estabilizadas de drogas esteroides
UA97496C2 (ru) Композиция укорененных мицеллярных наночастичек и способ ее получения
WO2006106519A3 (en) Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
UA87838C2 (ru) Стабилизированные перенасыщенные твердые растворы липофильных лекарствнных средств
CY1109564T1 (el) Σταθεροποιημενα υπερκορεσμενα στερεα λιποφιλων φαρμακων
MY143870A (en) Molecular dispersions of drospirenone
MX2007005124A (es) Composiciones farmaceuticas espontaneamente dispersables.
WO2011128633A3 (en) Oral pharmaceutical dispersion compositions
WO2007129311A3 (en) Nano-particles with contrast agents for diagnostic delivery system for x-ray and ct